Potential options for managing LOX+ ER- breast cancer patients

Yong Han, Shenyi Lian, Xingran Cui, Kexin Meng, B. Györffy, Tao Jin, Dongsheng Huang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Overexpression of lysyl oxidase (LOX) is often observed in estrogen receptor negative (ER-) breast cancer patients with bone metastasis. In the present bioinformatics study, we observed that LOX is a prognostic factor for poor progression free survival in patients with ER- breast cancer. LOX overexpression was positively correlated with resistance to radiation, doxorubin and mitoxantrone, but negatively correlated with resistance to bisphosphonate, PARP1 inhibitors, cisplatin, trabectedin and gemcitabine. LOX overexpression was also associated with EMT and stemness of cancer cells, which leads to chemotherapeutic resistance and poor outcome in ER- patients. Although we suggest several therapeutic interventions that may help in the management of LOX+ ER- breast cancer patients, experiments to validate the function of LOX in ER- breast cancer are still needed.

Original languageEnglish
Pages (from-to)32893-32901
Number of pages9
JournalOncotarget
Volume7
Issue number22
DOIs
Publication statusPublished - May 31 2016

Fingerprint

Protein-Lysine 6-Oxidase
Estrogen Receptors
Breast Neoplasms
trabectedin
gemcitabine
Mitoxantrone
Diphosphonates
Computational Biology
Cisplatin
Disease-Free Survival
Radiation
Neoplasm Metastasis
Bone and Bones

Keywords

  • Bisphosphonates
  • Chemoresistance
  • EMT
  • Estrogen recepter
  • LOX

ASJC Scopus subject areas

  • Oncology

Cite this

Han, Y., Lian, S., Cui, X., Meng, K., Györffy, B., Jin, T., & Huang, D. (2016). Potential options for managing LOX+ ER- breast cancer patients. Oncotarget, 7(22), 32893-32901. https://doi.org/10.18632/oncotarget.9073

Potential options for managing LOX+ ER- breast cancer patients. / Han, Yong; Lian, Shenyi; Cui, Xingran; Meng, Kexin; Györffy, B.; Jin, Tao; Huang, Dongsheng.

In: Oncotarget, Vol. 7, No. 22, 31.05.2016, p. 32893-32901.

Research output: Contribution to journalArticle

Han, Y, Lian, S, Cui, X, Meng, K, Györffy, B, Jin, T & Huang, D 2016, 'Potential options for managing LOX+ ER- breast cancer patients', Oncotarget, vol. 7, no. 22, pp. 32893-32901. https://doi.org/10.18632/oncotarget.9073
Han, Yong ; Lian, Shenyi ; Cui, Xingran ; Meng, Kexin ; Györffy, B. ; Jin, Tao ; Huang, Dongsheng. / Potential options for managing LOX+ ER- breast cancer patients. In: Oncotarget. 2016 ; Vol. 7, No. 22. pp. 32893-32901.
@article{e3c0096d81384c24af1c46d016fd8ede,
title = "Potential options for managing LOX+ ER- breast cancer patients",
abstract = "Overexpression of lysyl oxidase (LOX) is often observed in estrogen receptor negative (ER-) breast cancer patients with bone metastasis. In the present bioinformatics study, we observed that LOX is a prognostic factor for poor progression free survival in patients with ER- breast cancer. LOX overexpression was positively correlated with resistance to radiation, doxorubin and mitoxantrone, but negatively correlated with resistance to bisphosphonate, PARP1 inhibitors, cisplatin, trabectedin and gemcitabine. LOX overexpression was also associated with EMT and stemness of cancer cells, which leads to chemotherapeutic resistance and poor outcome in ER- patients. Although we suggest several therapeutic interventions that may help in the management of LOX+ ER- breast cancer patients, experiments to validate the function of LOX in ER- breast cancer are still needed.",
keywords = "Bisphosphonates, Chemoresistance, EMT, Estrogen recepter, LOX",
author = "Yong Han and Shenyi Lian and Xingran Cui and Kexin Meng and B. Gy{\"o}rffy and Tao Jin and Dongsheng Huang",
year = "2016",
month = "5",
day = "31",
doi = "10.18632/oncotarget.9073",
language = "English",
volume = "7",
pages = "32893--32901",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "22",

}

TY - JOUR

T1 - Potential options for managing LOX+ ER- breast cancer patients

AU - Han, Yong

AU - Lian, Shenyi

AU - Cui, Xingran

AU - Meng, Kexin

AU - Györffy, B.

AU - Jin, Tao

AU - Huang, Dongsheng

PY - 2016/5/31

Y1 - 2016/5/31

N2 - Overexpression of lysyl oxidase (LOX) is often observed in estrogen receptor negative (ER-) breast cancer patients with bone metastasis. In the present bioinformatics study, we observed that LOX is a prognostic factor for poor progression free survival in patients with ER- breast cancer. LOX overexpression was positively correlated with resistance to radiation, doxorubin and mitoxantrone, but negatively correlated with resistance to bisphosphonate, PARP1 inhibitors, cisplatin, trabectedin and gemcitabine. LOX overexpression was also associated with EMT and stemness of cancer cells, which leads to chemotherapeutic resistance and poor outcome in ER- patients. Although we suggest several therapeutic interventions that may help in the management of LOX+ ER- breast cancer patients, experiments to validate the function of LOX in ER- breast cancer are still needed.

AB - Overexpression of lysyl oxidase (LOX) is often observed in estrogen receptor negative (ER-) breast cancer patients with bone metastasis. In the present bioinformatics study, we observed that LOX is a prognostic factor for poor progression free survival in patients with ER- breast cancer. LOX overexpression was positively correlated with resistance to radiation, doxorubin and mitoxantrone, but negatively correlated with resistance to bisphosphonate, PARP1 inhibitors, cisplatin, trabectedin and gemcitabine. LOX overexpression was also associated with EMT and stemness of cancer cells, which leads to chemotherapeutic resistance and poor outcome in ER- patients. Although we suggest several therapeutic interventions that may help in the management of LOX+ ER- breast cancer patients, experiments to validate the function of LOX in ER- breast cancer are still needed.

KW - Bisphosphonates

KW - Chemoresistance

KW - EMT

KW - Estrogen recepter

KW - LOX

UR - http://www.scopus.com/inward/record.url?scp=84973574834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973574834&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9073

DO - 10.18632/oncotarget.9073

M3 - Article

C2 - 27147578

AN - SCOPUS:84973574834

VL - 7

SP - 32893

EP - 32901

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 22

ER -